IMMUNOTHERAPY

Immunotherapy, Wednesday 28 February 2018

last published: 01/Oct/17 16:25

Immunotherapy, Thursday 1 March 2018

08:45

Organiser's Welcome Remarks

08:50

Chair's Opening Remarks

Asia's Biotech Landscape:Innovation & Funding

Carolyn Ng
09:00

Venture capital funding for the biotech industry: A case study

It takes millions of dollars to transform an innovative idea to a commercially viable pharma product. Especially in developing countries where the government has other more important priorities than to invest in early stage companies, the role of the VC becomes even more crucial and necessary for success. Investigate how VC helps biotech to take flight in the competitive generics and biosimilar-focused Asia market.
 
John Connolly
09:20

Fostering biotech and bio-entrepreneurship in Asia: How do we build the next biotech unicorn in Southeast Asia?

Southeast Asia is extremely diverse. It is a home to near 620 million people across 11 countries, each with different languages and religions. Among the countries many are still in the developing stage where R&D is not as much a priority than providing necessity to minimise the income gap between the rich and the needy. Yet thriving biotech landscape offering innovative solutions is starting to be seen. What needs to be done to help these promising companies to fully realise their potential? How can ASEAN come together in supporting the biotech industry in the region, as well as building the next possible biotech unicorn in SEA?
 
Panel discussion
09:40

The Macro View: What will it take for Asia’s biotech industry to really flourish?

Everyone knows it is too generic to classify all Asian countries in a single category. With the exception of China and India, the remaining part of Asia is complicated, fragmented and diversified. With growing GDPs and middle class populations, the potential of Asia’s biotech industry is undeniable in the eye of global leaders. The main question is, how can government and related stakeholders assist the biotech industry to flourish to provide more affordable, personalised medicine for its populations? How do countries move away from a “me-too” to “me-first” mentality, especially when it comes to pharma R&D?
 
10:20

Speed Networking

10:30

Exhibition Visit & Networking Refreshments

Advanced Therapy Landscape Overview: Where does Asia fit?

Immunotherapy
10:55

Chair's Opening Remarks

Frank Jiang
Immunotherapy
11:00

Cancer precision medicine: From screening to drug selection and development

  • Personalised, affordable and high efficacy are the ideal criteria of a medicine. But the big question is how do we actually move towards providing highly personalised medicine to patients in need?
  • Investigate the pathway to the future of medicine, from drug discovery, development to reaching out to the patients.
Han Chong Toh
Immunotherapy
11:20

Awakening the immune system against cancer - Moving into the clinic

Is cancer immunotherapy the beginning of the end of cancer? Discover cases where immunotherapy can be used to treat complicated cancer cases, including leukaemia, breast cancer and more.
 
Immunotherapy
11:40

Enhancing regulation of advanced therapeutic products: How do we get there?

  • The importance of cross education and working closely with government representatives to ensure fair competition, whilst keeping patients’ interests front-of-mind
  • What is pharma’s role in influencing regulation crafting in Asia developing countries?
12:00

Roundtable Discussion Session

Now's your chance to get really interactive. Simply pick a table and join the debate. 

Table 10: What can we do to reconcile our diversified pharma regulations in Asia?

Table 11: Bringing it together: Roles of Patient, Pharma, Hospital and Government in Drug Development

Malini Raj, Chair, Australian Pituitary Foundation

Table 1: Upcoming vaccines in Asia and how to prepare for it

Table 2: Sustainable vaccines strategies in global health, high-income and private sector

Table 3: Sustainable biosimilar models in Asia

Table 4: Key strategies to overcome challenges in biosimilar development and manufacturing processes

Table 5: What can we learn fromCAR-T, PDL1, Cancer Vaccines successes, and what’s next in Asia?

Table 6: CRISPR & Precision medicine

Table 7: AI& Big data in drug discovery

Table 8: IoT and blockchain in clinical studies

Table 9: Pricing & Reimbursement strategies in Asia

12:50

Exhibition Visit & Networking Lunch

Cancer Vaccines

Immunotherapy
14:10

Chair's Opening Remarks

Cristina Chang
Immunotherapy
14:20

Breast cancer vaccines: What have we learnt so far?

  • Addressing the importance of breast cancer vaccines in Asia
  • Exploring unique challenges in Asia and strategies for developing cancer vaccines
  • Case study on OBI pharma
Victor Li
Immunotherapy
14:40

Anti-viral immunotherapy: A case study

Topic to be finalised
Victor Li, CEO, Lion TCR
Bandana Sharan
Immunotherapy
15:00

Dendritic cell vaccines in Asia: The first CDSCO approved Indian dendritic cell cancer immunotherapy

Discover the success story behind dendritic cell therapy for treatment of cancer, first of its kind in India
Bandana Sharan, Director, Research, APAC Biotech
15:20

Exhibition Visit & Networking Refreshments

Combination Immunotherapy

Jin San Yoo
Immunotherapy
16:00

Expansions of trials for with Avastin refractory recurrent GBM patients and combination of Tanibirumab + anti-PD1 antibody for refractory cancer patients

  • Insights learnt from Tanibirumab recurrent GBM phase IIa open labelled three arms multi centre trial in Australia 
  • Expansions of trails for with Avastin refractory recurrent GBM patients and combination of Tanibirumab + anti-PD1 antibody for refractory tumours
Jin San Yoo, President And Chief Executive Officer, Pharmabcine
Immunotherapy
16:20

Using genetic information to predict the effectiveness of combination immunotherapy

  • Using molecular analytics in creating effective combinations
  • Disease modelling and prediction with big data and analytics
  • Case study sharing
Immunotherapy
16:40

Creating immune modulator synergy in cancer management

  • Understanding why promising cancer vaccine trials fail
  • Exploring the roles of drug combination in favourably formulating positive immune responses in low dosages
  • Theoretical reasoning vs. reality: How do we maximise drug potential and minimise failure rates?
17:00

Networking Cocktail & Phar-East Industry Awards Presentation

last published: 01/Oct/17 16:25